Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead programs entering the clinic in atopic dermatitis.
The post Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs appeared first on MedCity News.
